Abstract:Background
Pregabalin (PGB) has been approved for the treatment of diabetic peripheral neuropathic pain (DPNP), but the mechanism of the PGB effect in this situation is not precisely known. Would it be via the reduction of inducible Nitric Oxide Synthase (iNOS) and thus the decrease of Nitric Oxide (NO) in type 2 diabetic patients? The current clinical trial was conducted to answer this question.
Methods
Twenty Seven diabetic patients with DPNP >